Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 23, 2009

Galapagos Receives $3.57M for Reaching Milestone in Osteoporosis Collaboration with Lilly

  • Galapagos reached a milestone in its osteoporosis collaboration with Eli Lilly, triggering a payment of €2.5 million from Lilly. To date Galapagos has received a total of €3.9 million in milestone fees.

    The original agreement, initiated in December 2007 with €3 million up front, provides Lilly access to 12 of Galapagos’ osteoporosis targets and drug discovery programs. Galapagos is eligible to receive up to €88 million for each target program in discovery, development, and regulatory milestones. Should a product be commercialized, Galapagos could receive up to €130 million in one-time sale-related milestones and up to double-digit royalties on worldwide sales.

    Galapagos is responsible for the development of drug candidates through to Phase IIa proof of concept. Lilly has the exclusive option to further develop and commercialize these candidates on a worldwide basis. Galapagos has the right to further develop and commercialize compounds for which Lilly does not exercise its option.

    The first milestone was achieved in July 2008 and triggered a €1 million fee. The current milestone was reached as one of the programs entered the next phase of medicinal chemistry operation. 

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »